PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Immune checkpoints inhibitors or MAPK inhibitors are currently used as standard of care therapies for patients with advanced melanoma. Here the authors report a phase 1 clinical trial testing the anti-PD-L1 antibody durvalumab in combination with the BRAF inhibitor dafrafenib and the MEK inhibitor t...

Full description

Bibliographic Details
Main Authors:	Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael Gordon, Leonel Hernandez-Aya, Donald Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy Mueller, Caroline Robert
Format:	Article
Language:	English
Published:	Nature Publishing Group 2020-12-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-020-19810-w

id	doaj-2021304222154fa1af9d43a174d21c40
record_format	Article
spelling	doaj-2021304222154fa1af9d43a174d21c402021-01-31T13:43:28ZengNature Publishing GroupNature Communications2041-17232020-12-0111111010.1038/s41467-020-19810-wPD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanomaAntoni Ribas0Alain Algazi1Paolo A. Ascierto2Marcus O. Butler3Sunandana Chandra4Michael Gordon5Leonel Hernandez-Aya6Donald Lawrence7Jose Lutzky8Wilson H. Miller9Katie M. Campbell10Bruno Delafont11Shannon Marshall12Nancy Mueller13Caroline Robert14University of California Los Angeles (UCLA) and Jonsson Comprehensive Cancer Center at UCLAUCSF Medical CenterIstituto Nazionale Tumori IRCCS Fondazione PascalePrincess Margaret Cancer CentreNorthwestern Memorial HospitalHonorHealth Research InstituteWashington University School of MedicineMassachusetts General HospitalMount Sinai Medical CenterSegal Cancer Center, Jewish General Hospital, Rossy Cancer Network, McGill UniversityUniversity of California Los Angeles (UCLA) and Jonsson Comprehensive Cancer Center at UCLAAstraZenecaAstraZenecaAstraZenecaGustave Roussy Cancer Campus and Paris-Saclay UniversityImmune checkpoints inhibitors or MAPK inhibitors are currently used as standard of care therapies for patients with advanced melanoma. Here the authors report a phase 1 clinical trial testing the anti-PD-L1 antibody durvalumab in combination with the BRAF inhibitor dafrafenib and the MEK inhibitor trametinib in patients with BRAFV600-mutant melanoma.https://doi.org/10.1038/s41467-020-19810-w
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Antoni Ribas Alain Algazi Paolo A. Ascierto Marcus O. Butler Sunandana Chandra Michael Gordon Leonel Hernandez-Aya Donald Lawrence Jose Lutzky Wilson H. Miller Katie M. Campbell Bruno Delafont Shannon Marshall Nancy Mueller Caroline Robert
spellingShingle	Antoni Ribas Alain Algazi Paolo A. Ascierto Marcus O. Butler Sunandana Chandra Michael Gordon Leonel Hernandez-Aya Donald Lawrence Jose Lutzky Wilson H. Miller Katie M. Campbell Bruno Delafont Shannon Marshall Nancy Mueller Caroline Robert PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma Nature Communications
author_facet	Antoni Ribas Alain Algazi Paolo A. Ascierto Marcus O. Butler Sunandana Chandra Michael Gordon Leonel Hernandez-Aya Donald Lawrence Jose Lutzky Wilson H. Miller Katie M. Campbell Bruno Delafont Shannon Marshall Nancy Mueller Caroline Robert
author_sort	Antoni Ribas
title	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
title_short	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
title_full	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
title_fullStr	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
title_full_unstemmed	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
title_sort	pd-l1 blockade in combination with inhibition of mapk oncogenic signaling in patients with advanced melanoma
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2020-12-01
description	Immune checkpoints inhibitors or MAPK inhibitors are currently used as standard of care therapies for patients with advanced melanoma. Here the authors report a phase 1 clinical trial testing the anti-PD-L1 antibody durvalumab in combination with the BRAF inhibitor dafrafenib and the MEK inhibitor trametinib in patients with BRAFV600-mutant melanoma.
url	https://doi.org/10.1038/s41467-020-19810-w
work_keys_str_mv	AT antoniribas pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT alainalgazi pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT paoloaascierto pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT marcusobutler pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT sunandanachandra pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT michaelgordon pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT leonelhernandezaya pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT donaldlawrence pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT joselutzky pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT wilsonhmiller pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT katiemcampbell pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT brunodelafont pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT shannonmarshall pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT nancymueller pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT carolinerobert pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma
_version_	1724316921197756416

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Similar Items